Medana Pharma S.A., Sieradz - søkeresultat

norspan 30 mikrog/ time

mundipharma as - buprenorfin - depotplaster - 30 mikrog/ time

Den europeiske union - norsk - EMA (European Medicines Agency)

bonviva

atnahs pharma netherlands b.v. - ibandronsyre - osteoporose, postmenopausale - legemidler til behandling av bein sykdommer - behandling av osteoporose hos postmenopausale kvinner med økt risiko for brudd (se punkt 5.. en reduksjon i risiko for vertebrale frakturer har blitt vist effekt på femoral nakke brudd har ikke blitt etablert.

Den europeiske union - norsk - EMA (European Medicines Agency)

celsunax

pinax pharma gmbh - ioflupane (123i) - radionuclide imaging; dementia; movement disorders - diagnostiske radiopharmaceuticals - dette legemidlet er kun til diagnostisk bruk. celsunax is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:in adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. celsunax is unable to discriminate between parkinson's disease, multiple system atrophy and progressive supranuclear palsy. hos voksne pasienter, for å kunne skille mellom sannsynlig demens med lewy legemer fra alzheimers sykdom. celsunax is unable to discriminate between dementia with lewy bodies and parkinson’s disease dementia.

Den europeiske union - norsk - EMA (European Medicines Agency)

bimzelx

ucb pharma s.a. - bimekizumab - psoriasis - immunsuppressive - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

Norge - norsk - Statens legemiddelverk

dolcontin 30 mg

mundipharma as - morfinsulfatpentahydrat - depottablett - 30 mg

Norge - norsk - Statens legemiddelverk

dolcontin 5 mg

mundipharma as - morfinsulfatpentahydrat - depottablett - 5 mg

Norge - norsk - Statens legemiddelverk

dolcontin 10 mg

mundipharma as - morfinsulfatpentahydrat - depottablett - 10 mg

Norge - norsk - Statens legemiddelverk

dolcontin 60 mg

mundipharma as - morfinsulfatpentahydrat - depottablett - 60 mg